Michel Goldman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michel Goldman has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
Fabienne Willems
Institute for Medical Immunology (IMI), Université Libre de Bruxelles (U.L.B), Charleroi, Belgium
11 shared publications- Stanislas Goriely
Universite Libre de Bruxelles
10 shared publications Alain Le Moine
Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium
8 shared publicationsDominique De Wit
Institute for Medical Immunology (IMI), Université Libre de Bruxelles (U.L.B), Charleroi, Belgium
7 shared publications- Valerie Verhasselt
Larsson‐Rosenquist Foundation Centre for Immunology and Breastfeeding, School of Medicine University of Western Australia Perth Western Australia Australia
6 shared publications - Ezra Aksoy
Center for Biochemical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
4 shared publications
Latest Publications
- Open Access
- 11 September 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 2114
100th Anniversary of Jules Bordet's Nobel Prize: Tribute to a Founding Father of Immunology
The 100th Anniversary of the Nobel Prize in Physiology or Medicine 1919 awarded to Jules Bordet offers the opportunity to underline the contributions of this Belgian doctor to the blooming of immunology at the end of the nineteenth century at the Institut Pasteur de Paris. It is also the occasion to emphasize his achievements as director of the Institut Pasteur du Brabant and professor at the Université libre de Bruxelles. Both in France and Belgium, he developed a holistic vision of immunology as a science at the crossroads of chemistry, physiology, and microbiology.
- 11 September 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 2114
Open Access100th Anniversary of Jules Bordet's Nobel Prize: Tribute to a Founding Father of Immunology
The 100th Anniversary of the Nobel Prize in Physiology or Medicine 1919 awarded to Jules Bordet offers the opportunity to underline the contributions of this Belgian doctor to the blooming of immunology at the end of the nineteenth century at the Institut Pasteur de Paris. It is also the occasion to emphasize his achievements as director of the Institut Pasteur du Brabant and professor at the Université libre de Bruxelles. Both in France and Belgium, he developed a holistic vision of immunology as a science at the crossroads of chemistry, physiology, and microbiology.
- Open Access
- 28 February 2019
- Published by Frontiers Media SA in Frontiers for Young Minds
- Vol. 7
Vaccines, Shots That Protect You
Tomorrow, your mother will take you to the doctor to receive your vaccines. Why do you need these shots since you are healthy and have already received some shots when you were just a baby? In this article, you will discover the reasons why booster vaccines are crucial, to protect you, your brothers and sisters but also your classmates and your friends.
- 28 February 2019
- Published by Frontiers Media SA in Frontiers for Young Minds
- Vol. 7
Open AccessVaccines, Shots That Protect You
Tomorrow, your mother will take you to the doctor to receive your vaccines. Why do you need these shots since you are healthy and have already received some shots when you were just a baby? In this article, you will discover the reasons why booster vaccines are crucial, to protect you, your brothers and sisters but also your classmates and your friends.
- Open Access
- 8 April 2016
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 3, 15
Education in Medicine: Moving the Boundaries to Foster Interdisciplinarity
Education in Medicine: Moving the Boundaries to Foster Interdisciplinarity
- 8 April 2016
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 3, 15
Open AccessEducation in Medicine: Moving the Boundaries to Foster Interdisciplinarity
Education in Medicine: Moving the Boundaries to Foster Interdisciplinarity
- 15 May 2009
- Published by Wolters Kluwer Health in Transplantation
- Vol. 87 (9S) , S99-S100
Transplantation Research: Will We Ever Reach the Holy Grail?
Journal ArticleResearch Support, Non-U.S. Gov'tReviewinfo:eu-repo/semantics/publishe
- 15 May 2009
- Published by Wolters Kluwer Health in Transplantation
- Vol. 87 (9S) , S99-S100
Transplantation Research: Will We Ever Reach the Holy Grail?
Journal ArticleResearch Support, Non-U.S. Gov'tReviewinfo:eu-repo/semantics/publishe
- 22 January 2009
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 156 (2) , 185-188
Translating transplantation tolerance in the clinic: where are we, where do we go?
Summary: Research networks dedicated to translation of immune tolerance in the clinic currently support pilot trials aiming at immunosuppression withdrawal in kidney or liver allograft recipients. Although results obtained so far indicate that significant hurdles still need to be overcome before organ transplant recipients can be weaned off drugs safely and routinely, recent advances suggest that immunosuppression minimization on the basis of validated biomarkers might become standard practice in a near future.
- 22 January 2009
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 156 (2) , 185-188
Translating transplantation tolerance in the clinic: where are we, where do we go?
Summary: Research networks dedicated to translation of immune tolerance in the clinic currently support pilot trials aiming at immunosuppression withdrawal in kidney or liver allograft recipients. Although results obtained so far indicate that significant hurdles still need to be overcome before organ transplant recipients can be weaned off drugs safely and routinely, recent advances suggest that immunosuppression minimization on the basis of validated biomarkers might become standard practice in a near future.
- 22 October 2008
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 38 (11) , 1705-1706
Sublingual immunotherapy: the quest for innovative adjuvants
- 22 October 2008
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 38 (11) , 1705-1706
Sublingual immunotherapy: the quest for innovative adjuvants
- 15 July 2008
- Published by Wolters Kluwer Health in Transplantation
- Vol. 86 (1) , 1-9
The Multiple Facets of Toll-Like Receptors in Transplantation Biology
Toll-like receptors (TLRs) belong to a family of pattern-recognition receptors for microbial products and endogenous molecules released by stressed cells. Experimental studies show that TLRs are involved in the process of acute allograft rejection and that their activation can prevent transplantation tolerance. Herein, we review the expression of TLRs and the impact of TLR signaling in different cell types in grafted organs including antigen-presenting cells, T and B lymphocytes, epithelial and endothelial cells. We then discuss the involvement of TLRs in the different phases of the rejection phenomenon and the impact of TLR-mediated events on regulatory circuits which dampen alloimmune responses.
- 15 July 2008
- Published by Wolters Kluwer Health in Transplantation
- Vol. 86 (1) , 1-9
The Multiple Facets of Toll-Like Receptors in Transplantation Biology
Toll-like receptors (TLRs) belong to a family of pattern-recognition receptors for microbial products and endogenous molecules released by stressed cells. Experimental studies show that TLRs are involved in the process of acute allograft rejection and that their activation can prevent transplantation tolerance. Herein, we review the expression of TLRs and the impact of TLR signaling in different cell types in grafted organs including antigen-presenting cells, T and B lymphocytes, epithelial and endothelial cells. We then discuss the involvement of TLRs in the different phases of the rejection phenomenon and the impact of TLR-mediated events on regulatory circuits which dampen alloimmune responses.
- Open Access
- 18 April 2008
- Published by Wiley in European Journal of Immunology
- Vol. 38 (5) , 1351-1357
DiC14‐amidine cationic liposomes stimulate myeloid dendritic cells through Toll‐like receptor 4
DiC14‐amidine cationic liposomes were recently shown to promote Th1 responses when mixed with allergen. To further define the mode of action of diC14‐amidine as potential vaccine adjuvant, we characterized its effects on mouse and human myeloid dendritic cells (DC). First, we observed that, as compared with two other cationic liposomes, only diC14‐amidine liposomes induced the production of IL‐12p40 and TNF‐α by mouse bone marrow‐derived DC. DiC14‐amidine liposomes also activated human DC, as shown by synthesis of IL‐12p40 and TNF‐α, accumulation of IL‐6, IFN‐β and CXCL10 mRNA, and up‐regulation of membrane expression of CD80 and CD86. DC stimulation by diC14‐amidine liposomes was associated with activation of NF‐κB, ERK1/2, JNK and p38 MAP kinases. Finally, we demonstrated in mouse and human cells that diC14‐amidine liposomes use Toll‐like receptor 4 to elicit both MyD88‐dependent and Toll/IL‐1R‐containing adaptor inducing interferon IFN‐β (TRIF)‐dependent responses.Supporting Information for this article is available at www.wiley‐vch.de/contents/jc_2040/2008/37998_s.pdf
- 18 April 2008
- Published by Wiley in European Journal of Immunology
- Vol. 38 (5) , 1351-1357
Open AccessDiC14‐amidine cationic liposomes stimulate myeloid dendritic cells through Toll‐like receptor 4
DiC14‐amidine cationic liposomes were recently shown to promote Th1 responses when mixed with allergen. To further define the mode of action of diC14‐amidine as potential vaccine adjuvant, we characterized its effects on mouse and human myeloid dendritic cells (DC). First, we observed that, as compared with two other cationic liposomes, only diC14‐amidine liposomes induced the production of IL‐12p40 and TNF‐α by mouse bone marrow‐derived DC. DiC14‐amidine liposomes also activated human DC, as shown by synthesis of IL‐12p40 and TNF‐α, accumulation of IL‐6, IFN‐β and CXCL10 mRNA, and up‐regulation of membrane expression of CD80 and CD86. DC stimulation by diC14‐amidine liposomes was associated with activation of NF‐κB, ERK1/2, JNK and p38 MAP kinases. Finally, we demonstrated in mouse and human cells that diC14‐amidine liposomes use Toll‐like receptor 4 to elicit both MyD88‐dependent and Toll/IL‐1R‐containing adaptor inducing interferon IFN‐β (TRIF)‐dependent responses.Supporting Information for this article is available at www.wiley‐vch.de/contents/jc_2040/2008/37998_s.pdf
- Open Access
- 28 January 2008
- Published by Wiley in European Journal of Immunology
- Vol. 38 (2) , 507-517
Interferon regulatory factor 7‐mediated responses are defective in cord blood plasmacytoid dendritic cells
Plasmacytoid dendritic cells (pDC) are specialized in massive production of type I interferons (IFN) upon viral infections. Activation of IFN regulatory factor (IRF)‐7 is critically required for the synthesis of type I IFN in pDC. IRF‐7 is highly expressed by resting pDC and translocates into the nucleus to initiate type I IFN transcription. In a previous work, we observed an impaired IFN‐α production in enriched cord blood pDC following a TLR9 stimulation using CpG oligonucleotides. Herein, we show that highly purified pDC from cord blood exhibit a profound defect in their capacity to produce IFN‐α/β in response to TLR9 as well as to TLR7 ligation or human CMV or HSV‐1 exposure. Microarray experiments indicate that expression of the majority of type I IFN subtypes induced by a TLR7 agonist is reduced in cord blood pDC. We next demonstrated a reduced nuclear translocation of IRF‐7 in cord blood pDC following CpG and HSV stimulation as compared to adult pDC. We conclude that impaired IRF‐7 translocation in cord blood pDC is associated with defective expression of type I IFN genes. Our data provide a molecular understanding for the decreased ability of cord blood pDC to produce type I IFN upon viral stimulation.
- 28 January 2008
- Published by Wiley in European Journal of Immunology
- Vol. 38 (2) , 507-517
Open AccessInterferon regulatory factor 7‐mediated responses are defective in cord blood plasmacytoid dendritic cells
Plasmacytoid dendritic cells (pDC) are specialized in massive production of type I interferons (IFN) upon viral infections. Activation of IFN regulatory factor (IRF)‐7 is critically required for the synthesis of type I IFN in pDC. IRF‐7 is highly expressed by resting pDC and translocates into the nucleus to initiate type I IFN transcription. In a previous work, we observed an impaired IFN‐α production in enriched cord blood pDC following a TLR9 stimulation using CpG oligonucleotides. Herein, we show that highly purified pDC from cord blood exhibit a profound defect in their capacity to produce IFN‐α/β in response to TLR9 as well as to TLR7 ligation or human CMV or HSV‐1 exposure. Microarray experiments indicate that expression of the majority of type I IFN subtypes induced by a TLR7 agonist is reduced in cord blood pDC. We next demonstrated a reduced nuclear translocation of IRF‐7 in cord blood pDC following CpG and HSV stimulation as compared to adult pDC. We conclude that impaired IRF‐7 translocation in cord blood pDC is associated with defective expression of type I IFN genes. Our data provide a molecular understanding for the decreased ability of cord blood pDC to produce type I IFN upon viral stimulation.
- 1 January 2008
- Vol. 29, S41-4
[Transplantation tolerance: European Union meets the challenge].
Recent developments in basic and translational immunology open new exciting perspectives for the induction of transplantation tolerance in the clinic. However, a number of hurdles still need to be overcome before immunosuppressive drugs can be safely withdrawn in solid organ transplant recipients. With this background, the European Commission recently launched several initiatives to tackle unmet needs in transplantation medicine. Herein, we focus attention on the RISET project, an ongoing collaborative effort across the European Union aiming at minimization of immunosuppression on the basis of validated biomarkers.
- 1 January 2008
- Vol. 29, S41-4
[Transplantation tolerance: European Union meets the challenge].
Recent developments in basic and translational immunology open new exciting perspectives for the induction of transplantation tolerance in the clinic. However, a number of hurdles still need to be overcome before immunosuppressive drugs can be safely withdrawn in solid organ transplant recipients. With this background, the European Commission recently launched several initiatives to tackle unmet needs in transplantation medicine. Herein, we focus attention on the RISET project, an ongoing collaborative effort across the European Union aiming at minimization of immunosuppression on the basis of validated biomarkers.